4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0001628280-26-026089
Chief Executive Officer sold 15,000 shares at $23.61 ($354,146)
- Chief Executive Officer acquired 37,760 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise 10b5-1 | +8,226 | $4.44 | $36,498 | 347,618 | D |
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise 10b5-1 | +7,454 | $3.79 | $28,249 | 355,072 | D |
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise 10b5-1 | +7,080 | $5.45 | $38,612 | 362,152 | D |
| Mazumdar Claire Chief Executive Officer | 2026-04-20 | Option exercise 10b5-1 | +15,000 | $3.79 | $56,847 | 377,152 | D |
| Mazumdar Claire Chief Executive Officer | 2026-04-20 | Sale 10b5-1 | −15,000 | $23.61 | $354,146 | 362,152 | D |
| Derivatives | |||||||
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,226 | 56,684 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,454 | 130,546 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-04-16 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,080 | 558,432 | D | ||
| Mazumdar Claire Chief Executive Officer | 2026-04-20 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −15,000 | 161,107 | D | ||
| Open-market sales · 15,000 sh · avg $23.61 · $354,146 | |||||||
Loading xslF345X06/wk-form4_1776727626.xml…